ICAM-1 / CD54

CD54 antibody LS-C46230 is an APC-conjugated mouse monoclonal antibody to human CD54 (ICAM-1). Validated for Flow, ICC, IHC and WB.

Antibodies Primary

Article No

LS-C46230-100

Species Reactivity

human

Size

100 tst

Clone

1H4

Source / Host

mouse

Shipping Information

RT

Application

FC, ICC, IHC, WB

Article No

LS-C46230-100

Species Reactivity

human

Size

100 tst

Clone

1H4

Source / Host

mouse

Shipping Information

RT

Application

FC, ICC, IHC, WB

Specifications

NCBI Number 3383
Application FC, ICC, IHC, WB
Article No LS-C46230-100
Country Availability SE, FI, DK, NO, FO, GL
Clone 1H4
Clone Type monoclonal
Conjugation APC
Description CD54 antibody LS-C46230 is an APC-conjugated mouse monoclonal antibody to human CD54 (ICAM-1). Validated for Flow, ICC, IHC and WB.
Supplier LifeSpan Biosciences
Entrez Gene ID 3383
Gene Symbol ICAM1
Immunogen Raji cells and spleen cells fused with NS1 cells
Isotype IgG2b
Notes CD54 antibody LS-C46230 is an APC-conjugated mouse monoclonal antibody to human CD54 (ICAM-1). Validated for Flow, ICC, IHC and WB.
Alias Names ICAM1, BB2, CD54 antigen, CD54, ICAM-1, p3.58
Product Type Antibodies Primary
Protocol The reagent is designed for Flow Cytometry analysis of human blood cells using 10 ul reagent / 100 ul of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Purification Size-exclusion Chromatography
Shipping Information RT
Size 100 tst
Source / Host mouse
Species Reactivity human
Storage 4°C
Substrate / Buffer PBS, 15mM sodium azide
Technical Specifications The antibody 1H4 reacts with CD54 (ICAM-1), a 85-110 kDa type I transmembrane glycoprotein (receptor for rhinovirus) expressed on activated endothelial cells, T lymphocytes, B lymphocytes, monocytes, macrophages, granulocytes and dendritic cells; the expression of CD54 is upregulated by activation.
Product Page Updated 2024-04-12T09:51:03.289Z
Volume 100 tst

Documentation

Shipping info
The delivery time for this item is approximately 9-18 business days. Read more